Major owner of Nivalis Therapeutics, Inc. was just granted 7,650 options

Peter A. Thompson, a major owner of Nivalis Therapeutics, Inc. and a director of the company, just received 7,650 options from the company. The strike price of the options received was $11.31, and these expire on January 01, 2028. Thompson now owns at least 7,650 options on the company.

Some additional info was provided as follows:

The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. 100% of the shares subject to the option become vested and exercisable on January 2, 2019. In accordance with the internal policies of OrbiMed Advisors LLC, the options received by Dr. Thompson must be held for the benefit of OrbiMed Advisors LLC and its affiliates.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Nivalis Therapeutics, Inc. Just Filed Its Quarterly Report: Net Loss Per ShareWe... - Aug. 9, 2018
Nivalis Therapeutics, Inc.'s See Remarks just declared ownership of no shares of Nivalis Therapeutics, Inc. - Aug. 8, 2018
Nivalis Therapeutics, Inc.'s See Remarks was just granted 150,000 options - Aug. 8, 2018
Nivalis Therapeutics: Alpine Immune Sciences Strengthens Leadership Team With Appointment Of Mark Litton As President And Chief Operating Officer - Aug. 6, 2018

Auto Refresh